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Lynch syndrome is associatedwith germ-linemutations in theDNAmismatch repair (MMR) genes,mainlyMLH1 andMSH2.Most
of themutations reported in these genes to date are pointmutations, small deletions, and insertions. Large genomic rearrangements
in the MMR genes predisposing to Lynch syndrome also occur, but the frequency varies depending on the population studied on
average from 5 to 20%. e aim of this study was to examine the contribution of large rearrangements in the MLH1 and MSH2
genes in a well-characterised series of 63 unrelated Southern Italian Lynch syndrome patients who were negative for pathogenic
point mutations in theMLH1,MSH2, andMSH6 genes. �e identi�ed a large novel deletion in theMSH2 gene, including exon 6
in one of the patients analysed (1.6% frequency). is deletion was con�rmed and localised by long-range PCR. e breakpoints
of this rearrangement were characterised by sequencing. Further analysis of the breakpoints revealed that this rearrangement was
a product of Alu-mediated recombination. Our �ndings identi�ed a novel Alu-mediated rearrangement within MSH2 gene and
showed that large deletions or duplications in MLH1 and MSH2 genes are low-frequency mutational events in Southern Italian
patients with an inherited predisposition to colon cancer.
1. Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC; also
known as Lynch syndrome) is an autosomal dominant
disorder characterised by colorectal cancer [1] that accounts
for 3–5% of all colorectal cancers. Aﬀected individuals have
approximately 60–80% lifetime risk of developing colorectal
cancer and women with Lynch syndrome have 54% risk of
developing endometrial cancer [2]. It is associatedwith germ-
line mutations in the DNA mismatch repair (MMR) genes,
mainlyMLH1 andMSH2 [3]. Mutations inMSH6 [4], PMS2
[5], and MLH3 [6] are less common. Recently, a germ-line
point mutation in MSH3 was found to be associated with
the Lynch syndrome phenotype [7]. Inactivation of theMMR
complex manifests microsatellite instability (MSI), which is
detected in tumour tissue [8].
e majority of mutations in the MMR genes so
far identi�ed are missense, nonsense, or small inser-
tions/deletions [http://www.insight-group.org/mutations
mutations]. Depending on the population studied, large
genomic rearrangements of the MMR genes constitute
various proportions of the germ-line mutations that
predispose to HNPCC [9–11]. Moreover, it seems that large
genomic rearrangements occur more frequently in some
populations than in others [11, 12]. e relative incidence of
genomic rearrangements among Lynch Syndrome families
appears to vary from 5–20% [13]. A systematic study
on genomic rearrangement in Lynch Syndrome showed
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that MLH1 and MSH2 are the most frequently targeted
MMR genes for this type of mutation [14]. Furthermore,
molecular characterisation of the breakpoints involved in
large rearrangements withinMLH1 andMSH2 genes showed
that the majority are caused by homologous recombination
between Alu repeats [15–17]. ese mutations are not
usually detected by conventional methods of mutation
analysis, such as denaturing high-performance liquid
chromatography (DHPLC) and direct DNA sequencing, but
they are detectable by a simple and robust technique such
as the Multiplex Ligation-Probe Dependent Ampli�cation
(MLPA) [18, 19] assay.
As little is known about the frequency of large rearrange-
ments in the MLH1 and MSH2 genes to Lynch syndrome
in Italian population, the aim of our study was to assess the
contribution of large genomic rearrangements in these two
genes in a well-characterised series of 63 Southern Italian
patients aﬀected by Lynch Syndrome.
2. Materials andMethods
2.1. Patients. Sixty-three families of Italian origin, 56 families
classi�ed according to the Amsterdam criteria [20] and 7
atypical Lynch families selected according to MSI high status
(MSI-H) [20], without germ-line pathogenic point mutations
in the MLH1, MSH2, or MSH6 genes, were recruited from
several health centres in Campania (Southern Italy).
All patients received genetic counselling and gave their
written informed consent to participate in this study.
2.2. Isolation of Genomic DNA. Total genomic DNA was
extracted from 4mL peripheral blood lymphocytes using
a Nucleon BACC2 Kit (Amersham Life Science) and from
tumour tissues and surgical margins by standard methods
[21].
2.3. Multiple� Ligation-Dependent Probe Ampli�cation
(MLPA). MLPA was performed using the SALSA MLPA
P003-B1MLH1/MSH2kit (MRC-Holland,eNetherlands)
according to the manufacturer’s instructions. Fragment
analysis was conducted on an ABI Prism 3130 Genetic
Analyser using GeneMapper soware (Applied Biosystems,
Foster City, CA, USA). Migration of fragments was
calculated by comparison to the GeneScan LIZ-500 size
standard (Applied Biosystems, Foster City, CA, USA).
Peak areas were then exported to a Microso spreadsheet
(www.MLPA.com) and calculations were done according
to the method described by Taylor and colleagues [22]. A
30–50% decrease in the peak area(s) indicated a deletion of
the corresponding exon(s), while a 30–50% increase in the
peak area(s) indicated a duplication of the corresponding
exon(s). MLPA results were con�rmed in at least two
independent experiments.
2.�. DNA Ampli�cation and Microsatellite Analysis. eMSI
status was con�rmedwith a �uorescentmultiplex system [23]
comprising six mononucleotide repeats (BAT-25, BAT-26,
BAT-40, NR-21, NR-24, and TGF𝛽𝛽RII) and four dinucleotide
repeats (D2S123, D5S346, D17S250, and D18S58). 20 ng
of DNA extracted by tumor tissue and peripheral blood
lymphocytes were ampli�ed in 25𝜇𝜇L reaction volume using
the CC-MSI Kit (Ab Analitica, Padova, Italy), in according to
manufacture instructions. e PCR products were analysed
by capillary electrophoresis analysis using an ABI Prism
3130 Genetic Analyser (Applied Biosystems, Foster City, CA,
USA).
2.5. RNA Analysis of MSH2 Gene. RNA was extracted from
4mL peripheral blood lymphocytes using a Trizol reagent
by standard methods (Quiagen). cDNA was synthesised
using SuperScript II RT (Invitrogen by Life Technologies)
and ampli�ed with primers that produced a 598-bp frag-
ment (2cFP 5�-GGCTCTCCTCATCCAGATTG and 2cRP
5�-AAGATCTGGGAATCGACGAA) spanning exons 4–7 of
the messenger RNA. e PCR products were analysed on a
2% agarose gel and visualised by ethidium bromide staining.
2.6. Long-Range Polymerase Chain Reaction and Breakpoint
Analysis. 500 ng of genomic DNA was ampli�ed in a 50 𝜇𝜇L-
reaction volume using 2.75mMMg2+, 500 𝜇𝜇Mof each dNTP,
2U of Expand Long Template PCR System (Expand Long
Template Buﬀer 2; Roche Diagnostics), and 300 nM of each
primer. Primers were designed between exon 5 and intron
7 of the MSH2 gene. is region was ampli�ed in four PCR
fragments.e same forward oligonucleotide (5FP) was used
in each reaction with a diﬀerent reverse oligonucleotide, each
approximately 1000 bp apart (Table 1). Cycling conditions
were as follows: 94∘C for 2min, followed by 10 cycles con-
sisting of 94∘C for 10 sec, 60∘C for 30 sec (−0.5∘C/cycle) and
68∘C for 15min, followed by 25 cycles consisting of 94∘C for
15 sec, 57∘C for 30 sec, and 68∘C for 15min (+20 sec/cycle),
and �nishing with one cycle at 68∘C for 7min.
All oligonucleotides were designed using Primer3 So-
ware (http://frodo.wi.mit.edu/primer3/) and checked using
the Basic Local Alignment Search Tool program (BLAST,
http://blast.ncbi.nlm.nih.gov/Blast.cgi).
2.7. Sequencing Analysis. e PCR products were sequenced
in both the forward and reverse directions using anABIPrism
3100 Genetic Analyser (Applied Biosystems, Foster City, CA,
USA).
2.8. In Silico Analysis. e nucleotide sequences of the
genomic MSH2 region (NG_007110.1) were analysed with
the RepeatMasker program (http://repeatmasker.org/) using
the default settings. Sequence comparisons in RepeatMasker
were performed by the program cross_match [24].
3. Results
3.1. Detection of Large Genomic Rearrangements in the MSH2
and MLH1 Genes by MLPA. MLPA analysis on 63 unrelated
patients identi�ed a deletion in theMSH2 gene in one patient
only (1.6%) (Figure 1). is deletion removed exon 6, which
is located between the small intron 5 and the large intron
6. e exon 6 deletion was con�rmed at the RNA level by
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T 1: Primer sequences used for long-range PCR to characterise the breakpoints of the MSH2 exon 6 deletion.
Primer Sequence Nucleotide position (NG_007110.1) Amplicon size (bp)
5FP GGATATTGCAGCAGTCAGAGCCC 11258–11280
7RP AGAGTGAGTCACCACCACCAACT 26890–26913 15657 bp
6RPl AGCTTTTCTGGAGGCCATAGGCA 24694–24717 13459 bp
6RPi AGTCTGGTCCAAGGATCACCAGCA 23620–23644 12386 bp
6RPh TCGTCGGTGGAAGAGGTGGCT 22565–22586 11328 bp
6RPg AGCCCATGAAGAGAGCTGACACC 21580–21603 10345 bp
RT/PCR sequencing of a fragment with a lower molecular
weight.e deletion was identi�ed in a 39-year-old man with
a family history of colorectal cancer, who had developed a
tubulovillous adenoma with small fragments of mucinous
adenocarcinoma in the rectum, approximately 75 cm from
the anus. e same deletion was also detected in his 33-
year-old brother. Although the brother was asymptomatic,
endoscopy revealed an adenocarcinoma located proximal to
the hepatic �exure (Figure 2).
3.2. Microsatellite Analysis. MSI analysis was performed on
DNA extracted from tumour tissues (adenocarcinoma), and
surgical margins of both patients (the proband and his
brother) carrying the MSH2 exon 6 deletion. Both patients
were found to have an MSI-H status, with instability at all
markers analysed (data not shown).
3.3. Breakpoint Characterisation of theMSH2Exon 6Deletion.
e breakpoints of the exon 6 deletion within the MSH2
gene were characterised by analysing the intragenic regions
between exon 5 and exon 7. is region was ampli�ed
using region-speci�c oligonucleotides, as described in the
Materials and Methods section. One forward primer located
in exon 5, and diﬀerent reverse primers starting in exon 7
were used. Abnormal fragment products of 3804, 2731, 1673
and 690 bp were ampli�ed from the patient�s DNA but not
from the DNA of the healthy control using the primer pairs
5FP/6RPl, 5FP/6RPi, 5FP/6RPh, and 5FP/6RPg, respectively.
No ampli�cation products were obtained using the primer
pair 5FP/7 RP.
As shown in Figure 3, sequence analysis of the 690-
bp ampli�cation product obtained using the primer pair
5FP/6RPg revealed the loss of a 9655-bp genomic region.
e 5� breakpoint is located in intron 5, in a strech
of 11 nucleotides located 1,535–1,525 nt before the �rst
nucleotide of exon 6. e 3� breakpoint is located in
intron 6, in an identical sequence of 11 nucleotides located
5,325–5,315 nt before the �rst nucleotide of exon 7. e
exact breakpoints could not be ascertained because of the
presence of an identical 11-bp sequences at both ends.
is deletion c.942+(346–356)_1077-(5323–5313)del, alter-
natively NC_000002.11:g.47641903_47651558del, is named
in accordance with the mutation nomenclature instructions
provided by the HGVS (http://www.hgvs.org/); it creates a
premature stop codon and the formation of a truncated
protein.
3.4. In Silico Analysis. Using the RepeatMasker program, the
5� and 3� breakpoints of the 9655-bp deletion were found
to lie within the 26-bp core sequence of two Alu elements,
which share 96% homology and diﬀer by only one nucleotide.
Both Alu elements belong to the AluSx subfamily and were
269 bp and 310 bp, respectively. Homology analysis of the
AluSx sequences included in the deletion was performed
using BLAST analysis (Figure 4).
e entireMSH2 genewas also analysed byRepeatMasker
program, as already described in the literature [25], to verify
the presence of repeat sequences. In this study, a total of 190
repeat sequences, including 106 Alu-type SINE sequences, 19
L1-type LINE sequences, 12 simple repeat sequences, and 12
LTR sequences were identi�ed, and their positions on the
gene de�ned. Of these, 32 Alu-type SINE sequences, one
L1-type LINE sequence, one LTR, and three simple repeat
sequences were located in the genomic region between exons
5 and 7.
4. Discussion
e Lynch syndrome, caused primarily by germ-line point
mutations within MMR genes, is also associated with large
rearrangements that account for 5–20% of all mutations.
Here, we report the results of our screening for large rear-
rangements in the MLH1 and MSH2 genes in a cohort of 63
Southern Italian patients who were negative for pathogenic
point mutations in the MLH1, MSH2, and MSH6 genes. We
identi�ed one large rearrangement in the MSH2 gene and
none in the MLH1 gene. erefore, large rearrangements in
the MLH1 and MSH2 genes occur at a low frequency in our
patient cohort (1.6%).
e rearrangement in MSH2 identi�ed in this study
caused a large deletion that removed exon 6 and was
detected in two patients from the same family who met the
Amsterdam-1 criteria. e two aﬀected brothers presented
colorectal cancer with early-onset, before 40 years of age.
Other family members were also aﬀected (not tested in
this study) and presented with the same phenotype (Figure
2). DNA extracted from the tumour tissues of the two
patients showed an MSI-H status, with instability at all
markers analysed. e novel deletion is 9,655 bp long and
extends from a region 346 bp downstream of exon 5 to
5323 bp upstream of exon 7. e exact breakpoints could
not be ascertained because of the presence of identical 11-
bp sequences at both ends; in fact using the RepeatMasker
program, the breakpoints of this deletion were found to lie
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(b)
F 1: MLPA analysis reveals a candidate genomic rearrangement in the MSH2 gene. (a)e electropherogram of the DNA patient: the
arrow shows half the level of ampli�cation of exon � in the carrier sub�ect. (b) e electropherogram of the DNA healthy control: the arrow
shows normal level of ampli�cation of exon �.
CRC 39
CRC 40
CRC 38CRC 34
F 2: Family pedigree of the patient with the large MSH2 gene deletion. Symbols and abbreviations used are denoted as follows. Arrows:
analysed members of family; black symbol: colorectal cancer; CRC, colorectal cancer. Number next to diagnosis denote age at oneset; •: not
detected.
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(b)
F 3: Con�rmation and characterisation of the MSH2 exon 6 deletion. (a) Agarose gel electrophoresis (1.5%) of the long-range PCR
product obtained using the forward primer located in exon 5 (5FP) and the reverse primers located in intron 6 (6RPg) (as described in the
text); DNA Molecular Weight Marker III (Roche) used. An abnormal 690 bp fragment was obtained for our patient. (b) Sequence analysis
of the truncated 690-bp PCR amplicon reveals the loss of a 9,655-bp genomic region. e breakpoints highlighted in yellow are located in a
strech of 11 nucleotides common to both introns 5 and 6.
Intron 5
Intron 5
Intron 6
Intron 6
Exon 6 AluSxAluSx
(a)
GTTAATTTTTATATTTTTAGTAGGGTTGCGGGGACAGGGTTTCACCATGTTGGCCAGGTT
GCTAATTTTTGTATTTTTAGTAGAG ------- GACAGGGTTTCGCCATGTTGGCCAGGCT
AluSx intron 5
AluSx intron 6
(b)
F 4: Detailed characteristics of Alu-mediated MSH2 exon 6 deletion. (a) Scheme of the MSH2 deletion showing that the 9655-bp
deletion is located between two AluSX elements in introns 5 and 6. (b) Alignment of the two AluSX elements reveals a core 11-bp sequence
identical in both introns at the breakpoint.
within the 26-bp core of two AluSx sequences that share 96%
homology. As these twoAluSx sequences were found to diﬀer
by only one nucleotide, it is possible that recombination could
occur at this sequence. erefore, we speculated that the
MSH2 rearrangement is most likely an Alu-Alu homologous
recombination event that deletes approximately 9.5 kb of the
MSH2 genomic region encompassing exon 6.
e complete deletion of exon 6 has been previously
reported to cause Lynch syndrome in a Dutch family
[26], however the deletion was classi�ed as resulting from
nonhomologous recombination, as the breakpoints did not
fall in Alu sequences. e breakpoint characterised in this
study therefore demonstrates that we have identi�ed a novel
deletion.
e MSH2 and MLH1 genes are known to have a high
density of Alu sequences, 34% and 21%, respectively, several
large rearrangements in this gene have been reported [16,
27]. However, given the high frequency with which these
repetitive sequences occur within these two genes, we would
expect the overall incidence of large rearrangements in our
cohort to be much higher than that identi�ed. erefore, it
is reasonable to hypothesise that Alu-mediated homologous
recombination could also cause intragenic rearrangements,
such as translocations or inversions, that are not always
detectable with the MLPA assay used in this study. MLPA
is used for detecting copy number changes in genomic
DNA and can only detect large deletions or duplications.
Inability to detect intragenic rearrangements could in part
explain the low frequency of these molecular alterations in
our cohort. Moreover, it is noteworthy that an exceptionally
low frequency of large rearrangements in the MLH1 and
MSH2 genes (<1.5%) was also reported in a study of the
Spanish population [11]; indeed, due to historical inheritage
Spaniards share a common genetic pool with the Southern
Italian population. In contrast, other studies performed
especially on populations of Northern-Europe (including
Northern Italy population) have reported an increasingly
higher frequency of large rearrangements in these two genes
[28, 29], with a recent study of Slovak HNPCC [12] reporting
a frequency of 25%. Moreover, diﬀerences in the frequency
of large rearrangements are also seen in other Alu-rich genes
that are responsible for hereditary diseases, such as BRCA1,
and BRCA2, STK11, depending on the population analysed
[30, 31]. erefore, based on these informations the Alu
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sequences may be regarded as passive elements that serve as
favourable substrates for recombination and the molecular
mechanism that promotes recombination events remains to
be clari�ed.
Beyond possible explanations about the low frequency
of large rearrangements in our population, it should be
highlighted that the majority of patients with Lynch syn-
drome tested in this study do not have a mutation in the
MMR genes most frequently mutated. It is also important to
emphasize that our families were selected on the basis of the
Amsterdam clinical criteria and MSI-H, thus there is good
evidence that all aﬀected have a strong genetic component
to early development of cancer. We therefore suggest that
some undiscovered genetic mechanism in Lynch syndrome
patients is yet to be investigated. Recently, it has been shown
that unclassi�ed genetic variants in MMR genes can behave
as low-risk alleles that contribute to the risk of colon cancer
in Lynch syndrome families when interacting together or
with other low-risk alleles in other MMR genes [7, 32].
Furthermore, it is also possible that the existence of other
as yet undiscovered genes may confer susceptibility to colon
cancer in Lynch syndrome families. e EPCAM gene in
addition toMMR genes has already been associated HNPCC
phenotype [33] as well asMYH in addition to APC gene has
been associated FAP phenotype [34]. Recently, association
studies have identi�ed a number of loci that appear confer
more increases in colon cancer risk [35, 36]. Further studies
are needed to better identify the underlying genetic risk
factors associated with disease in these families.
5. Conclusions
is paper is the �rst signi�cant study on contribution of
largeMLH1 andMSH2 genomic rearrangements in Southern
Italian Lynch syndrome patients, negative for point mutation
in MMR genes. Our results enlarge the spectrum of large
rearrangements inMSH2 genes and at the same time indicate
that these genomic rearrangements seem to be a less frequent
mutational event in our population. Nonetheless, we believe
that the detection of large rearrangements in the MLH1 and
MSH2 genes should be included in the routine testing for
Lynch syndrome, especially considering the simplicity of the
MLPA assay.
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